公开(公告)号：US20240360117A1

公开(公告)日：2024-10-31

申请号：US18420855

申请日：2024-01-24

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Kaicheng Zhu ,  Kevin McGrath ,  Solymar Negretti-Emmanuelli ,  Adam Szymaniak ,  Jianming Yu ,  In Jong Kim ,  Yat Sun Or

IPC: C07D413/14 ,  A61K31/5513 ,  A61K45/06 ,  A61P31/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P31/14 ,  C07D417/14 ,  A61K31/5513 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240360083A1

公开(公告)日：2024-10-31

申请号：US18507013

申请日：2023-11-10

Applicant: Agios Pharmaceuticals, Inc.

Inventor： Francesco G. Salituro ,  Jeffrey O. Saunders ,  Shunqi Yan

IPC: C07D215/36 ,  A61K31/497 ,  A61K31/5513 ,  C07D215/40 ,  C07D239/42 ,  C07D241/20 ,  C07D243/08 ,  C07D271/12 ,  C07D277/64 ,  C07D277/68 ,  C07D295/192 ,  C07D319/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D215/36 ,  A61K31/497 ,  A61K31/5513 ,  C07D215/40 ,  C07D239/42 ,  C07D241/20 ,  C07D243/08 ,  C07D271/12 ,  C07D277/64 ,  C07D277/68 ,  C07D295/192 ,  C07D319/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  Y02P20/582

Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

公开(公告)号：US12129248B2

公开(公告)日：2024-10-29

申请号：US16335951

申请日：2017-09-25

Applicant: Dana-Farber Cancer Institute, Inc.

Inventor： James Bradner ,  Jun Qi ,  Alexander Federation ,  Zoe Jacobson ,  Anthony Varca

IPC: C07D417/12 ,  A61P35/00 ,  C07D277/54 ,  C07D405/04 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D417/12 ,  A61P35/00 ,  C07D277/54 ,  C07D405/04 ,  C07D417/14 ,  C07D471/04

Abstract: Provided herein are compounds useful as inhibitors of CBX. Also described are pharmaceutical compositions and medical uses of these compounds.

公开(公告)号：US12129244B2

公开(公告)日：2024-10-29

申请号：US18513418

申请日：2023-11-17

Applicant: Escient Pharmaceuticals, Inc.

Inventor： Marion Lanier ,  Marcus Boehm ,  Liming Huang ,  Esther Martinborough ,  Marcos Sainz ,  Brandon Selfridge ,  Adam Yeager

IPC: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

Abstract: Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20240352009A1

公开(公告)日：2024-10-24

申请号：US18694173

申请日：2022-10-26

Applicant: HODOGAYA CHEMICAL CO., LTD.

Inventor： Kouki KASE ,  Byung-Sun YANG ,  Moon-Chan HWANG ,  Junichi IZUMIDA ,  Yuta HIRAYAMA ,  Shuichi HAYASHI

IPC: C07D417/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  H10K85/60

CPC classification number: C07D417/10 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  H10K85/615 ,  H10K85/631 ,  H10K85/654 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576

Abstract: In order to prevent deterioration inside an organic EL element and significantly improve the light extraction efficiency, an object of the present invention is to provide a compound that absorbs light rays with wavelengths of 400 to 410 nm of sunlight, thereby preventing them from affecting a material inside the element, and has a high refractive index in a wavelength range of 450 to 750 nm. The present invention provides an amine compound having a specific benzazole ring structure having a high refractive index. An organic EL element having excellent light emission efficiency is obtained by using the compound of the present invention as a material constituting a capping layer.

公开(公告)号：US20240352008A1

公开(公告)日：2024-10-24

申请号：US18687794

申请日：2022-04-14

Applicant: GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD.

Inventor： Tao LI ,  Zhijun LONG ,  Jingyao SONG

IPC: C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07D519/00 ,  H10K85/60

CPC classification number: C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14 ,  C07D487/04 ,  C07D519/00 ,  H10K85/622 ,  H10K85/633 ,  H10K85/654 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576

Abstract: The present disclosure provides an organic compound, a light extraction layer material, and an organic electronic device. The organic compound has a structure represented by formula (1). X1 and X2 are independently selected from O, S, or NR1; L1 and L2 are independently selected from a single bond, a substituted or unsubstituted aromatic group having 6 to 30 ring atoms, or a substituted or unsubstituted heteroaromatic group having 5 to 30 ring atoms; M1 and M2 are independently selected from a substituted or unsubstituted aromatic group having 6 to 60 ring atoms, a substituted or unsubstituted heteroaromatic group having 5 to 60 ring atoms, or a substituted or unsubstituted amino group.

公开(公告)号：US20240351999A1

公开(公告)日：2024-10-24

申请号：US18569148

申请日：2022-06-10

Applicant: INSTITUTE OF MATERIA MEDICA ,CHINESE ACADEMY OF MEDICAL SCIENCES

Inventor： Song WU ,  Wenxuan ZHANG ,  Xintong ZHAO ,  Qingyun YANG ,  Jing FENG ,  Jie ZHANG ,  Chi ZHANG ,  Zunsheng HAN ,  Tianlei LI ,  Jie XIA ,  Kun ZHANG ,  Bo LIU ,  Huihui SHAO ,  Yue WANG ,  Yuhua HU ,  Xinyu LUO ,  Hanyilan ZHANG ,  Xu LIAN ,  Zihao ZHU

IPC: C07D401/14 ,  A61K31/454 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  A61P31/04 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  A61K31/454 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  A61P31/04 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention belongs to the technical field of antibacterial drugs, and discloses a pyrrolylacylpiperidylamine compound and use thereof. The present invention in particular relates to a pyrrolylacylpiperidylamine compound and a pharmaceutically acceptable salt thereof, and use thereof in the preparation of a medicament for resisting infections with bacteria, mycoplasma or chlamydia. The compound has a structure shown in the following general formula:

公开(公告)号：US20240336611A1

公开(公告)日：2024-10-10

申请号：US18547190

申请日：2022-02-23

Applicant: Insilico Medicine IP Limited

Inventor： Aleksandrs ZAVORONKOVS ,  Aleksandr ALIPER ,  Vladimir ALADINSKIY ,  Andrey KUKHARENKO ,  Luoheng QUIN ,  Xin CHENG

IPC: C07D471/08 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4995 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10

CPC classification number: C07D471/08 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/4995 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10

Abstract: Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.

公开(公告)号：US20240335448A1

公开(公告)日：2024-10-10

申请号：US18376981

申请日：2023-10-05

Applicant: Servier Pharmaceuticals LLC

Inventor： Zenon Konteatis ,  Janeta Popovici-Muller ,  Jeremy Travins ,  Robert Zahler ,  Zhenwei Cai ,  Ding Zhou

IPC: A61K31/53 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D251/18 ,  C07D251/48 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

CPC classification number: A61K31/53 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D251/18 ,  C07D251/48 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

公开(公告)号：US12110295B2

公开(公告)日：2024-10-08

申请号：US17254345

申请日：2019-06-21

Applicant: Icahn School of Medicine at Mount Sinai ,  The University of North Carolina at Chapel Hill

Inventor： Jian Jin ,  Gang Wang ,  Jing Liu ,  Xufen Yu ,  Dongxu Li

IPC: C07D487/04 ,  C07D401/14 ,  C07D417/14

CPC classification number: C07D487/04 ,  C07D401/14 ,  C07D417/14

Abstract: Disclosed herein are WD40 repeat domain protein 5 (WDR5) degradation/disruption compounds including a WDR5 ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of WDR5-mediated diseases.